lofexidine: Clinical Trials

14 trials of lofexidine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 14 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 8, Active not recruiting 3, Terminated 2, Recruiting 1
Phase 32Completed 2
Phase 11Active not recruiting 1

Follow lofexidine: new trials by email Literature Review of lofexidine trials Research Report on lofexidine

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
LFX/PGB, LFX/PLA-PGB - Opiate Withdrawal Syndrome, Opioid Use
Phase 2TerminatedUniversity of Pennsylvania1122024-09-012026-11-16
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
Standard of Care with Lofexidine, Standard of Care without Lofexidine - Opioid Withdrawal (Disorder)
Phase 2Active not recruitingBioCorRx Pharmaceuticals Inc242023-10-022025-10-01
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 1 / Phase 2Active not recruitingNew York State Psychiatric Institute1602023-02-282026-10-28
Evaluating Buspirone to Treat Opioid Withdrawal
Buspirone, Lofexidine, Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 2RecruitingUniversity of Maryland, Baltimore1002022-12-152026-08-24
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment - Opioid Withdrawal, Opioid Use Disorder
Phase 2Active not recruitingUniversity of Maryland, Baltimore602021-12-012026-11-12
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
Lofexidine, Placebo oral tablet - Post Traumatic Stress Disorder, Opioid-use Disorder
Phase 2CompletedPharmacotherapies for Alcohol and Substance Use Disorders Alliance842021-03-092026-05-08
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab - Opioid Withdrawal
Phase 2CompletedUniversity of Pennsylvania902020-12-172024-09-19
An Innovative Intervention for OUD Treatment
Bridge Device, Lofexidine, Placebo - Opioid-Related Disorders, Opioid Dependence
Phase 2 / Phase 3CompletedJohns Hopkins University362020-11-152026-06-09
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Lofexidine 0.18 MG - Opioid-use Disorder
Phase 2CompletedNew York State Psychiatric Institute202019-09-012021-12-09
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
Lofexidine, Placebo - Opioid Withdrawal (Disorder)
Phase 2TerminatedUSWM, LLC (dba US WorldMeds)42019-08-022024-10-21
Impact of Lofexidine on Stress, Craving and Opioid Use
Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence
Phase 2CompletedMedical University of South Carolina1122019-06-262025-02-07
Combined Pharmacotherapy for Cannabis Dependency
Dronabinol, Placebo, Lofexidine - Cannabis Dependence, Marijuana Dependence
Phase 2 / Phase 3CompletedNew York State Psychiatric Institute1562010-01-012019-04-24
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
Lofexidine, dronabinol, Marijuana - Marijuana Dependence
Phase 2CompletedNew York State Psychiatric Institute82005-08-012013-02-05
Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
Lofexidine, Placebo - Opioid-Related Disorders
Phase 2CompletedYale University862005-02-012015-07-30

Conditions studied

Opioid-Related Disorders (8)  ·  Marijuana Abuse (2)  ·  Anxiety Disorders (1)  ·  Stress Disorders, Post-Traumatic (1)

Sponsors

New York State Psychiatric Institute (4)  ·  University of Maryland, Baltimore (2)  ·  University of Pennsylvania (2)  ·  BioCorRx Pharmaceuticals Inc (1)  ·  Johns Hopkins University (1)  ·  Medical University of South Carolina (1)  ·  Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (1)  ·  USWM, LLC (dba US WorldMeds) (1)  ·  Yale University (1)

Countries

United States (14)

Top investigators

Cecilia Bergeria, Ph.D. (1)  ·  Christopher D. Verrico, PhD (1)  ·  Eric Strain (1)  ·  Frances R Levin, M.D. (1)  ·  John Peppin, DO (1)  ·  Kelly E Dunn, Ph.D, M.B.A. (1)  ·  Margaret Haney, Ph.D. (1)  ·  Rajita Sinha (1)  ·  Sandra Comer, Ph.D (1)  ·  Stuart Watson (1)  ·  Thomas R Kosten, MD (1)

Results publications

PMID 29457671, PMID 34737091

NIH funding

P50DA009236 (1), R01DA019239 (1), R01DA048761 (1), R01DA052937 (1), U54DA016511 (1), UG3DA056247-01 (1)